FOOD AND DRUG ADMINISTRATION

First Page		Document Content
Monoclonal antibodies Pyridines Eisai Eribulin Pralatrexate Denosumab Pfizer Amgen Food and Drug Administration Pharmacology Chemistry Pharmaceutical sciences		FOOD AND DRUG ADMINISTRATION Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 103,36 KB Share Document on Facebook

	Application of Natural Resources to Drug Discovery in Eisai Research and Development of Eribulin mesylate Katsuya Tagami, Eisai Co., Ltd. Eribuin mesylate is a first-in class, non-taxane microtubule dynamics inhibitor th DocID: 1uZFZ - View Document
	EISAI UND PIQUR UNTERZEICHNEN EINEN BAHNBRECHENDEN KOOPERATIONSVERTRAG ÜBER DIE UNTERSUCHUNG VON HALAVEN® (ERIBULIN) UND PQR309 BEI SCHWER BEHANDELBAREM BRUSTKREBS Der Vertrag sieht die Anwendung von Eribulin in Kombin DocID: 1rWLP - View Document
	EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor i DocID: 1rhhk - View Document
	Legend Open to Accrual Pending Accrual on Hold Advanced Breast Cancer DocID: 18i4E - View Document
	January 13, 2015 Eisai Co., Ltd. STATEMENT REGARDING NHS ENGLAND’S REASSESSMENT OF HALAVEN® FOR THE CANCER DRUGS FUND Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that, in DocID: 13EAt - View Document